Скачать или смотреть MDMA's Real-World Impact | SoRI 2025 Issuer Update (CSE:MDMA)

🎙️ On the Canadian Securities Exchange (CSE) Issuer Update series, part of this year’s Summit on Responsible Investment, James Black sits down with Nick Kadysh, CEO & President of PharmAla Biotech Holdings Inc. (CSE:MDMA), the world’s only commercial supplier of clinical-grade MDMA for PTSD treatment.

Nick shares PharmAla’s mission: providing safe, regulated access to MDMA-assisted therapy in Canada and Australia, developing novel MDMA analogs with improved safety profiles, and supporting global clinical trials exploring new uses for MDMA. Backed by real-world evidence showing remarkable patient outcomes, PharmAla’s work is transforming mental health care—and opening doors for regulatory change.

With new markets opening, including the EU and partnerships like Cortexa in Australia, PharmAla is expanding access to life-changing therapies while advancing research. The company is also pioneering tools like a prescriber portal and CME programs to support Canadian doctors and patients.

🌎 As Nick says, “What better thing can you imagine than giving people back a piece of their soul?”

#AlwaysInvested

#CSEUpdates #PharmAla #MDMA #PTSD #MentalHealthAwareness #ImpactInvesting #DrugDevelopment #AIinBiotech #PsychedelicsForPTSD #CSEIssuerUpdate #SoRI2025 #ClinicalTrials #HealthcareInnovation #InvestorRelations